Diplomat Pharmacy (DPLO) Misses Q3 EPS by 3c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- US stock futures tumble as Trump says Iran deal is 'over', oil climbs
- Oil jumps over 4% to two-week high after Trump says deal with Iran 'over'
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
Diplomat Announces 3rd Quarter Financial Results
November 2, 2016 4:17 PM EDTFLINT, Mich., Nov. 2, 2016 /PRNewswire/ --Â Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, announced financial results for the quarter ended September 30, 2016. Â All comparisons, unless otherwise noted, are to the quarter ended September 30, 2015.
Third Quarter 2016 Highlights include:
Revenue of $1,181 million, an increase of 25% or $234 million 12% organic revenue growth Total prescriptions dispensed of 266,000, an increase of 9% Gross margin of 6.6% versus 8.0% Gross profit per prescription dispensed of $289, compared to $301... More